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Abstract
Background:  An insertion/deletion polymorphism in the α2B-adrenoceptor (AR) has been
associated with the risk for acute myocardial infarction (AMI) and sudden cardiac death. In this
study we tested whether this polymorphism is associated with the risk for AMI among members
of families with type 2 diabetes.
Methods: 154 subjects with a history of AMI were matched for age and sex with one of their
siblings who did not have a history of AMI. The prevalence of the genotypes of the α2B-AR
insertion/deletion polymorphism was compared between the siblings using McNemar's test. We
also explored the data to see whether this genetic variation affects the risk for hypertension by
using logistic regression models in the two subpopulations of subjects, with and without a history
of AMI.
Results: Among all study subjects, 73 (24%) carried the α2B-AR deletion/deletion genotype, 103
(33%) carried the insertion/insertion genotype, and 132 (43%) were heterozygous. The distribution
of genotypes of the α2B-AR insertion/deletion variation in the group of subjects with a history of
AMI and their phenotype-discordant siblings did not statistically significantly differ from that
expected by random distribution (p = 0.52): the deletion/deletion genotype was carried by 34
subjects with AMI (22%), and by 39 subjects without AMI (25%). Neither did we observe any
significant difference in deletion allele frequencies of the α2B-AR insertion/deletion polymorphism
between patients with a history of AMI (0.44) and their sib-pair controls (0.46, p = 0.65). In an
exploratory analysis, the α2B-AR deletion/deletion genotype was associated with increased odds
for hypertension compared with subjects carrying any of the other genotypes.
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Conclusions: The deletion/deletion genotype of the α2B-AR does not emerge in this study as a
risk factor for AMI among members of families with type 2 diabetes; however, it might be involved
in the development of hypertension.
Background
Vascular disease is the major cause of morbidity and mor-
tality in patients with diabetes mellitus [1]. In vivo studies
in humans have shown that α2-adrenoceptors (ARs)
mediate constriction of large and small coronary arteries
[2], an effect augmented by atherosclerosis [3], and medi-
ate peripheral vasoconstriction [4]. However, lack of α2-
AR subtype-selective drugs has precluded the clarification
of the precise roles of each subtype in these responses to
α2-AR activation. Based on studies on genetically engi-
neered mice lacking the α2-AR A or B or C subtype, it has
been demonstrated that the α2B-AR subtype mediates
peripheral vasoconstriction [5].
A variant form of the human α2B-AR gene encodes a recep-
tor protein with deletion of three glutamate residues [6].
Studies on transfected cells have revealed that this dele-
tion variant manifests significantly impaired agonist-pro-
moted receptor desensitization [7]. In vivo studies in
humans have associated the deletion/deletion (DD) gen-
otype with reduced flow-mediated dilatation of the bra-
chial artery [8], and reduced coronary blood flow and
increased peripheral resistance upon adrenaline infusion
[9]. In a population-based, prospective study on 912 mid-
dle-aged men, the DD genotype was associated with an
increased incidence of acute myocardial infarction (AMI)
in comparison to the other two genotypes [10]. In another
population of men who died suddenly outside of a hospi-
tal, the DD genotype was associated with increased rela-
tive risks for AMI and sudden cardiac death [11]. The
relative risks for AMI and sudden cardiac death were espe-
cially high in men who died before the age of 55 [11].
To explore the possible effect of the insertion/deletion
variation in the α2B-AR gene on the risk for AMI in a pop-
ulation at high risk for type 2 diabetes and cardiovascular
disease, we conducted a study on 154 sibling-pairs from
Finland, discordant for AMI. We hypothesized that the
DD genotype will be more prevalent among patients with
a history of AMI than among their phenotype-discordant
sib-pairs. We also explored the possibility that the DD




This study had a phenotype-discordant sib-pair design
with AMI as the selection phenotype. 154 subjects (88
men, 66 women) from eastern [12] and western [13] Fin-
land who reported having had an AMI were selected from
families with type 2 diabetes participating in the Botnia
study [13]. Each case-subject was matched for sex and age
with one of his or her siblings who had not had an AMI.
Characteristics of the study population are presented in
Table 1. Before participating in the study, voluntary
informed written consent was obtained from each subject.
The study protocol was approved by the ethics committee
of Lund University.
Using a multiple-risk-factor assessment equation [14],
with complete data available for 79% of the study popu-
lation, global risk-assessment scoring was calculated, and
the age-stratified relative risk for coronary heart disease
was estimated. The majority of the subjects (60%) had
above average relative risk for coronary heart disease
(26% moderately above average relative risk, 34% high
relative risk), 27% had below average relative risk, and
13% had an average relative risk. Taking into account the
relatively old age of the subjects in this population (44%
over 70 years, 63% over 65 years), the absolute risk for
coronary heart disease in this population may thus be
considered high.
Phenotypic characterization of the study subjects
A standardized health questionnaire was filled by a
trained nurse together with the subject, covering medical
history, including current medication (use of any drug
prescribed by a physician at the time of examination), and
smoking and alcohol consumption habits. A subject was
defined as a smoker if he or she had smoked for a period
of at least one year.
Myocardial infarction was defined as an acute coronary
event requiring hospitalization; the information was veri-
fied against the subject's hospital records.
A subject was classified as having hypertension if he or she
had systolic blood pressure (BP) ≥ 160 mmHg, or diasto-
lic BP ≥ 90 mmHg, or was treated with antihypertensive
medication [15]. Diagnosis of type 2 diabetes mellitus
was based upon the WHO criteria of 1998 [15].
Measurements and assays
BP was measured three times from the right arm at 5 min
intervals with the subject in seated position after a 30 min
rest, and the mean of the three values was used. This pro-
cedure followed well established routines of how to meas-
ure BP [16].Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/15
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Serum total cholesterol, HDL cholesterol, and triglyceride
concentrations were measured on a Cobas Mira analyzer
(Hoffman LaRoche, Basel, Switzerland). The LDL choles-
terol concentrations were calculated using the Friedewald
formula.
Genotyping
Genomic DNA was extracted from whole blood using
standard methods. The method used to genotype the α2B-
AR insertion/deletion polymorphism was based on PCR
amplification and DNA electrophoresis, and has been
described elsewhere [10].
Statistical analyses
Paired t tests (for continuous variables) and McNemar's
test (for discrete variables) were used in the characteriza-
tion of the population. Since the study population was
sampled as sibling pairs, analysis of the entire population
according to the three genotypes must take into account
the possibility that error terms are not independent but
are correlated between siblings. We therefore used linear
mixed models with the genotype group information as a
fixed factor, and the sib-pair information as a random
factor to characterize the genotype groups. The effect of
the α2B-AR insertion/deletion polymorphism on the risk
for AMI was estimated by the difference in the frequency
of the DD genotype between the phenotype-discordant
sibling pairs, and was tested using McNemar's test. Odds
ratios for hypertension and their 95% confidence inter-
vals (95% CI) were calculated using logistic regression
models. Using a univariate logistic regression model, the
effect of the different genotypes of the α2B-AR insertion/
deletion variation on the odds for hypertension was
explored. In multivariate logistic regression models, age,
sex, smoking, diabetes, body mass index, serum LDL cho-
lesterol, and the α2B-AR genotype were added as covariates
in a conditional stepwise fashion with p = 0.05 for entry
and 0.1 for removal. Statistical computations were per-
formed with SPSS/Win version 11.0.1 software (SPSS Inc.,
Chicago, IL, USA).
Results
Genotype information was obtained for all 308 subjects.
Of these, 73 (24%) carried the DD genotype, 103 (33%)
the insertion/insertion (II) genotype, and 132 (43%) the
insertion/deletion (ID) genotype. Except for hyperten-
sion, no differences (p > 0.1) in major risk factors for cor-
onary heart disease were found between the α2B-AR
insertion/deletion genotype groups (Table 1).
The prevalence of the DD genotype did not statistically
significantly differ between subjects with a history of AMI
and their sib-pair controls (p = 0.5): the DD genotype was
carried by 34 subjects with AMI (22%), and by 39 subjects
without AMI (25%). Neither did we observe any signifi-
cant difference in D allele frequencies of the α2B-AR inser-
tion/deletion polymorphism between patients with a
history of AMI (0.44) and their sib-pair controls (0.46, p
= 0.65).
To explore the possible association of the α2B-AR inser-
tion/deletion variation and hypertension, we compared
the prevalence of hypertension in the genotype groups. In
subjects with no history of AMI, the DD genotype was
associated with increased odds for hypertension when
compared with the II genotype group (odds ratio (OR)
3.7, 95% CI 1.2–11.1, p = 0.021), or when compared with
the II + ID genotype groups combined (OR 3.2, 95% CI
1.2–8.9, p = 0.026) (Table 2). Among subjects with AMI,
there were only 16 individuals who were not classified as
hypertensive according to the employed criteria, and no
Table 1: Characterization of the study population by AMI phenotype and the α2B-adrenoceptor insertion/deletion genotype.
Phenotype Genotype
AMI (n = 154) No AMI (n = 154) P DD (n = 73) ID (n = 132) II (n = 103) P ID + II (n = 235) P (vs. DD)
Age (years) 67.1 ± 0.8 66.9 ± 0.8 0.59 66.7 ± 1.0 67.0 ± 0.8 67.2 ± 1.0 0.35 67.1 ± 0.6 0.45
BMI (kg/m2) 28.0 ± 0.3 27.2 ± 0.3 0.038 28.1 ± 0.5 27.2 ± 0.4 27.9 ± 0.5 0.62 27.5 ± 0.3 0.43
Systolic BP (mmHg) 143 ± 1 145 ± 2 0.38 145 ± 2 144 ± 2 143 ± 2 0.81 144 ± 1 0.56
Diastolic BP (mmHg) 80.0 ± 0.9 82.1 ± 1.0 0.063 80.8 ± 1.1 81.7 ± 1.0 80.2 ± 1.2 0.62 81.1 ± 0.8 0.94
LDL cholesterol (mmol/l) 3.71 ± 0.09 3.76 ± 0.08 0.44 3.82 ± 0.11 3.70 ± 0.10 3.71 ± 0.10 0.84 3.71 ± 0.07 0.55
HDL cholesterol (mmol/l) 1.13 ± 0.02 1.27 ± 0.03 <0.001 1.19 ± 0.02 1.18 ± 0.03 1.19 ± 0.04 0.57 1.20 ± 0.03 0.32
Hypertension 127 (89%) 101 (70%) <0.001 60 (53) 96 (97) 72 (78) 0.049 168 (175) 0.023
Smoking 76 (56%) 50 (38%) <0.001 25 (29) 57 (55) 44 (42) 0.75 101 (97) 0.47
Diabetes 115 (75%) 90 (58%) 0.002 47 (49) 87 (88) 71 (69) 0.80 158 (156) 0.53
Data for continuous variables are presented as mean ± SEM. Discrete variables are presented as number of subjects, and in parenthesis, either 
percentage of the group for which data are available (AMI phenotype) or the expected number by random distribution (α2B-adrenoceptor insertion/
deletion genotype). Paired t test and McNemar's test were used to calculate the p value comparing the siblings discordant for history of AMI. Linear 
mixed models were used to calculate the p values in the comparison of the genotype groups.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/15
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statistically significant associations were found between
the α2B-AR genotypes and hypertension.
In subjects that were not treated with an antihypertensive
drug, a trend for increased systolic and diastolic BP was
observed among those carriers of the α2B-AR DD genotype
who had not had AMI (Table 3).
Discussion
The main finding of this study is a lack of association
between the α2B-AR DD genotype and AMI among mem-
bers of families with type 2 diabetes. Another finding of
this study is a possible association between this genotype
and hypertension.
Association with AMI
Earlier, association of the α2B-AR DD genotype with AMI
was reported in a population-based prospective study on
912 middle-aged men from eastern Finland [10], and in a
series of 700 unselected sudden out-of-hospital deaths of
Finnish men subjected to medico-legal autopsy [11]. The
populations in these studies were younger than the popu-
lation of the current study, and their relative risk for coro-
nary heart disease was expected to be similar to the
general population. The lack of association between the
α2B-AR DD genotype and AMI in high-risk subjects
observed in the present study may suggest that the mech-
anism by which the α2B-AR deletion variant confers its
observed increased risk for AMI is not directly dependent
on established coronary heart disease risk factors that lead
to atherosclerosis, and that in subjects at high risk for cor-
onary heart disease the effect of this genetic variation is
Table 2: Odds ratios for hypertension in relation to the α2B-adrenoceptor genotype and other cardiovascular risk factors.
N (hypertensives) AMI 143 (127) No AMI 144 (101)
OR (95% CI) P OR (95% CI) P
Univariate models
α2B-AR D vs. I 1.6 (0.6–4.7) 0.36 1.8 (0.9–3.7) 0.12
α2B-AR ID vs. II 1.4 (0.4–4.1) 0.59 1.3 (0.6–2.8) 0.53
α2B-AR DD vs. II 2.6 (0.5–13.2) 0.26 3.7 (1.2–11.1) 0.021
α2B-AR DD vs. II + ID 2.2 (0.5–10) 0.36 3.2 (1.2–8.9) 0.026
Age 1.0 (0.9–1.0) 0.79 1.1 (1.0–1.1) 0.008
BMI 1.1 (1.0–1.4) 0.037 1.1 (1.0–1.2) 0.038
LDL cholesterol 1.3 (1.0–1.8) 0.059 1.5 (1.0–2.2) 0.032
Smoking 0.6 (0.2–2.0) 0.43 0.5 (0.2–1.2) 0.11
Diabetes 1.9 (0.6–5.8) 0.29 1.3 (0.6–2.7) 0.48
Multivariate model*
α2B-AR DD vs. II + ID N/A 4.0 (1.2–13.3) 0.024
Age N/A 1.1 (1.0–1.1) 0.020
BMI N/A 1.2 (1.0–1.4) 0.006
LDL cholesterol N/A 1.8 (1.1–3.0) 0.032
Results are from univariate and conditional multivariate logistic regression models. *Data are presented for the last step of the stepwise conditional 
insertion of variables into the models. Adjustment was done for age, sex, smoking, diabetes, BMI, and LDL cholesterol, which were inserted into a 
multivariate logistic regression model in a stepwise manner (p = 0.05 for entry and 0.1 for removal). N/A denotes not applicable (all the variables 
were rejected by the models). I, insertion; D, deletion; BMI, body mass index
Table 3: Blood pressure (mmHg) of subjects not treated with an antihypertensive drug, according to α2B-AR I/D genotypes
AMI No AMI
DD (n = 3) ID (n = 12) II (n = 8) P* ID + II (n = 20) P* DD (n = 14) ID (n = 26) II (n = 32) P* ID + II (n = 58) P*
Systolic BP 144 ± 9 144 ± 3 130 ± 6 0.090 139 ± 3 0.54 154 ± 8 136 ± 4 146 ± 4 0.043 141 ± 3 0.055
Diastolic BP 86 ± 5 83 ± 3 77 ± 3 0.28 81 ± 2 0.43 86 ± 4 77 ± 2 82 ± 2 0.067 80 ± 1 0.065
*One-way ANOVA was used in the comparison of BP between the three genotype groups; t test was used in the comparison of BP of carriers of 
the DD genotype with carriers of the other genotypes combined. I, insertion; D, deletionCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/15
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diluted. This interpretation was supported by the mor-
phometric autopsy findings of the sudden death study
[11]. In that study [11], the DD genotype was associated
with increased odds for AMI and sudden cardiac death,
but not with the severity of coronary atherosclerosis.
Association with hypertension and BP
In subjects that had not had an AMI, the DD genotype was
associated in univariate logistic regression analysis with
increased odds for hypertension. However, since this
analysis was conducted as further exploration of the data
rather than based on an a priori hypothesis, adjustment for
multiple testing should be employed. A corrected p value
corresponding to 0.05 when testing 2 independent
hypotheses would be 0.0253 (based on the equation α =
1 - 0.951/N where N is the number of hypotheses tested).
The observed p value for the association between the DD
genotype and hypertension (about 0.02) has therefore
only borderline statistical significance.
Two previous studies explored the possible involvement
of the α2B-AR insertion/deletion variation in the develop-
ment of hypertension, and reported lack of association
[10,18]. However, in the study on 912 middle-aged men
[10], the prevalence of cardiovascular risk factors was dif-
ferent from that of the current study, making it difficult to
compare the results of the studies. Because of the very low
frequency of the DD genotype (n = 3) among the subjects
in the study on 155 sib-pairs concordant for hypertension
[18], that study can be considered to have insufficient
power to detect linkage between the α2B-AR DD genotype
and the studied phenotype.
Several earlier studies have suggested a role for the α2B-AR
in the development of hypertension. α2-adrenergic vaso-
constriction in humans [4] is probably mainly mediated
by the α2B-AR subtype [5], and the observed decreased
agonist-promoted desensitization property of the deletion
variant [7] may suggest that the DD genotype confers
increased vasoconstriction that leads to increased periph-
eral resistance – a common finding in hypertension [19].
Furthermore, rodent studies suggest a significant role for
the α2B-AR in acquired and hereditary hypertension [20-
22]. Additionally, loci on human chromosome 2 have
been linked with increased BP and hypertension in several
recent genome-wide studies [23,24]. So far, the location
of the human α2B-AR gene (ADRA2B, GeneBank accession
number M34041) on chromosome 2 has been tentatively
placed at 2p13-q13, but more precise mapping will be
needed to confirm or exclude the α2B-AR gene as the
hypertension risk gene involved in these genome-wide
linkage study results.
Methodological considerations
Using a health questionnaire, a subject was categorized as
a smoker if he or she had smoked for a period of at least
one year. This information may be considered insufficient
to provide a complete estimation of the impact of this risk
factor on the total risk for AMI.
Interpretation of results from studies with a case-control
design, where the studied risk factor may also affect sur-
vival, such as in the present study, is not straightforward.
Inherently by the study design, only survivors of an acute
coronary event were included as index cases in the present
study – possibly creating selection bias. Such an effect was
demonstrated by Hamajima et al. [17], who showed that
the effects of genotypes increasing disease risk and fatality
rate are underestimated, while those increasing the risk
and improving prognosis are overestimated.
It should also be acknowledged that the apparently unaf-
fected sibs were themselves at higher risk for AMI on the
basis of family history, both by belonging to high-risk
type 2 diabetes families and by having a sib with AMI.
Thus, the unaffected sib may also become affected in a
short time.
Conclusions
To conclude, the results of this study suggest that the α2B-
AR insertion/deletion variation either does not play a sig-
nificant role in AMI morbidity in members of families
with type 2 diabetes that are at high risk for cardiovascular
diseases, or that by affecting mortality, the DD genotype
could be underrepresented among the surviving AMI
cases. We also propose a role for this genetic variation in
the development of hypertension; however, further stud-
ies are required to replicate this finding.
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